IL-13 involvement in eosinophilic esophagitis: Transcriptome analysis and reversibility with glucocorticoids

 Supported in part by National Institutes of Health grants AI070235 and AI45898 (M.E.R.), the Food Allergy and Anaphylaxis Network (M.E.R.), the Campaign Urging Research for Eosinophil Disorders, the Buckeye Foundation (M.E.R.), the Food Allergy Project (M.E.R.), the American Heart Association 0625296B (C.B.), the Thrasher Research Funds NR-0014 (C.B.), the Instituto Carlos III Fondo de Investigación Sanitaria CD05/00060 (M.V.), Public Health Service grant CA102357 (S.I.W.), the Translational Research Initiative, Cincinnati Children's Hospital Medical Center, and the DHC (NIDDK 064403).

 Disclosure of potential conflict of interest: M. E. Rothenberg has consulting arrangements with Ception Therapeutics and Merck, owns stock in Ception Therapeutics, and is on the speakers' bureau for Merck. The rest of the authors have declared that they have no conflict of interest.

 Transcript profiling is available online at http://cypher.cchmc.org:1104. The reader should login as a guest and select “HG-U133 genome”; experiments and gene lists are located in the folder named MRothenberg/blanchard et al.

PII: S0091-6749(07)01974-4

doi: 10.1016/j.jaci.2007.10.024

© 2007 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.